Loading clinical trials...
Loading clinical trials...
An Exploratory Clinical Study on the Safety and Efficacy of Autologous Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CG-102-12C) in the Treament of Advanced Hepatocellular Carcinoma
Conditions
Interventions
CG-102-12C
Locations
2
China
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
First Affiliated Hospital, Medical College of Zhejiang University
Hangzhou, Zhejiang, China
Start Date
June 28, 2025
Primary Completion Date
March 31, 2027
Completion Date
July 31, 2027
Last Updated
January 22, 2026
NCT06737913
NCT01101906
NCT04212221
NCT04985136
NCT04605796
Lead Sponsor
Zhejiang University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions